
ABOUT ISR REPORTS
Industry Standard Research – ISR Reports – is a full-service market research company operating exclusively in the pharmaceutical and pharmaceutical services industry. ISR’s syndicated and custom market research capabilities coupled with unparalleled industry expertise and experience, enables our customers to make smarter, more informed business decisions.
ISR’s syndicated reports are produced using direct feedback from decision-makers (primary market research) which enables us to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to our customers.
While our syndicated reports cover a wide-range of topics within the industry, sometimes clients have specific questions that need answering or they are searching for a certain target. ISR designs dozens of proprietary custom market research projects for clients every year. These studies are often used to assess new products and services, gauge customer satisfaction, measure brand strength, or test marketing messages.
ISR knows the industry. We have presented at bid defenses, owned P&Ls, written proposals to RFPs, designed and implemented marketing strategies, and negotiated strategic partnerships. These experiences translate to our work products. ISR operates exclusively in the pharmaceutical and pharmaceutical services industry, our knowledge of the space is current and detailed.
Give us a call or send us an email, we are always open to a conversation. If we can help we will, and if not, we will tell you.
You can also download our brochure here.
E-BOOKS
-
Empower decision-makers while helping CDMOs tailor their strategies to better meet sponsor needs through reliable benchmark data, grounded in rigorous methodology.
-
In observing the strategic partnerships between CDMOs and drug developers, learn which characteristics experts say developers should prioritize when evaluating contract manufacturers.
-
As clinical trials become increasingly complex, it is more important than ever to understand how to overcome patient recruitment challenges in order to accelerate timelines, lower costs, and improve the quality of clinical trial data.
-
This e-book examines the rationale behind how CROs are selected, why they are retained, and why sponsors opt for one provider or outsourcing model versus another.
-
Hybrid trials have undergone rapid evolution in the past few years. Examine this evolution, the reasons for confidence and concern, and how they may impact pharmaceutical development in the future.
-
It can be difficult to find industry specific, easy to interpret, trustworthy market data. Read the available eBook to discover free drug development and manufacturing facts, figures, and expert perspectives.
CONTACT INFORMATION
ISR Reports
5565 Centerview Drive
Raleigh, NC 27606
UNITED STATES
Phone: 919-301-0106
INFOGRAPHICS
- Small Molecule Drug Substance Outsourcing Drivers
- Biologic Drug Substance Outsourcing Drivers
- Outsourced Bioprocessing By Respondent Location
- The Right Choice: Using Consultants For CDMO Selection
- Drug Innovators’ Outlook On Innovative Treatments
- Reactor Technology’s Influence On CDMO Selection
- Preference Among Users: New And Emerging Biopharma
- Use Of Preferred Providers Among Large Molecule Outsourcers
- Biologic Drug Product Outsourcing Drivers By Company Size
- Large Molecule Drug Substance Pandemic Complications
- Biologic Sterile Injectable Outsourcing Volume
- Manufacturing Costs For Large Molecule Development Work
- Using The Same CDMO For Development And Commercial Manufacturing
- The Pandemic’s Influence: Biologic Drug Substance Outsourcing Risk
- Biologic Drug Substance Outsourcing
- Large Molecule vs Small Molecule Drug Product Outsourcing
- Reasons CDMOs Lose Oral Dose Manufacturing Bids
- Reasons CDMOs Lose Sterile Injectable Manufacturing Bids
- Reasons CDMOs Lose Bioprocessing Bids
- Biologic Drug Product Outsourcing
- Changes In Manufacturing Pipeline Focus
- 3 Year Rolling Average – Biologic API Customer Loyalty
- Top Five Oral Dosage Forms By Portfolio Composition
- How Experience, Capacity Shape Sterile Injectables Outsourcing
- How Do Experience And Capacity Impact Small Molecule API Outsourcing?
- Top Five Satisfaction Drivers For Outsourced Oral Dose Manufacturing
- Top Five Satisfaction Drivers For Outsourced Bioprocessing
- Customer Loyalty In Biologic Drug Product Manufacturing
- Biologic Drug Substance And Drug Product Preferred Provider Use
- How Do Experience And Capacity Impact Oral Dose Outsourcing?
- Outsourcing Drivers By Company Size
- Most Difficult Aspects Of Biosimilar Manufacturing
- How Experience & Capacity Influence Biologic API Outsourcing
- What Factors Influence Outsourcing Model Changes
- Outsourcing Impact Of Focus On Innovative Treatment
- Change Of Focus For Biopharma Manufacturers
- Projected Biologics Portfolios In 2023
- What Will Drive Biologics Market Growth?
- Small Molecule Outsourcing Drivers
- Small Molecule API Contract Manufacturer Loyalty
- Comparison Of Selling vs. Manufacturing Biosimilars
- Benefits Of Using Preferred Providers For Clinical Development Outsourcing
- Outsourced Manufacturing: Comparing Large Vs. Small Molecule
- Outsourcers’ CMO Preferences
- Use Of Preferred Providers Among Biologic Outsourcers
- Improving Manufacturing Outsourcing Relationships
- Customer Loyalty In Small Molecule Drug Product Manufacturing
- Outsourcing Practices And CMO Opinions
FEATURED ARTICLES
- Slide Down The Funnel To Stand Out
- Results From The 2023 CDMO Leadership Awards
- Tracking The Evolution Of CDMO Selection Criteria
- Applying Industry Benchmarks To Dictate Your CDMO Choice
- Cryobag Container Development For Cell & Gene Therapies
- CDMO Selection In 5 Simple Steps
- Where Bioprocessing Outsourcers Stand On Capacity Concerns
- Industry Trends: CDMO Outsourcing
- Industry Trends: Clinical Logistics Outsourcing
- Biologics Outsourcing Differences By Company Size
- Outsourcing Highly Potent API – It’s What You Know And Who You Know
- How Service Providers Can Create Momentum In An Established Brand
- Outsourcers Are Feeling Uneasy About Continuity Of Supply
- Understanding CDMO Selections: Getting It Right
- Have CDMO Selection Criteria Changed Over The Past Five Years?
- What’s Happening In Cell & Gene Therapy Development?
- Outsourcing Drivers For Small Molecule Manufacturing
- Manufacturing Expenditure By Activity
- Standing Out In The Crowded Biopharma CDMO Market
- Outsourcing Success Requires Constant Evolution
- Industry Trends In Clinical Development Technology
- Do Strategic Partnerships Meet Outsourcers Expectations?
- Trends In Bioprocessing CDMO Selection
- Sponsor Challenges When Outsourcing Sterile Injectables
- CMOs Continue To Exceed Sponsor Expectations
- COVID-19's Impact On Outsourced Manufacturing
- Areas Of Growth For Oral-Dose Outsourcing
- Insights Into The Competitive Clinical Manufacturing Market
- Letting Motivations Guide The Outsourcing Approach
- Revealing Response To A Hypothetical Question About Outsourcing Services
- Is OSD Becoming More Complicated?
- Small & Emerging Outsourced Manufacturing Activities
- Small And Emerging Biopharma Companies Outsourcing Practices
- How To Improve Outsourcing Relationships
- Are Preferred Provider Agreements The Best Model For Outsourcing?
- Why Is It So Hard To Select A CMO?
- Warming Up To Hybrid Trials